

This listing of claims will replace all prior versions of claims in the application.

Claim 1. (original) A method for the prevention or treatment of an extravascular hematoma or blood clot in a subject, comprising administering to the subject a therapeutically effective amount of a thrombolytic agent, thereby preventing or treating the extravascular hematoma or blood clot.

Claim 2. (original) The method of claim 1, wherein the blood clot is associated with intraventricular hemorrhage.

Claim 3. (original) The method of claim 2, wherein the blood clot is further associated with intracerebral hemorrhage.

Claim 4. (original) The method of claim 1, wherein the blood clot is associated with subarachnoid hemorrhage.

Claim 5. (currently amended) The method of ~~claim 1~~ any of claims 1-4, wherein the thrombolytic agent is urokinase.

Claim 6. (currently amended) The method of ~~claim 1~~ any of claims 1-4, wherein the thrombolytic agent is t-PA or rt-PA.

Claim 7. (currently amended) The method of ~~claim 1~~ any of claims 1-6, wherein the thrombolytic agent is administered in conjunction with EVD.

Claim 8. (currently amended) The method of ~~claim 1~~ any of claims 1-7, wherein the thrombolytic agent is first administered between about 12-24 hours after diagnosis of intraventricular hemorrhage, intracerebral hemorrhage, and/or subarachnoid hemorrhage.

Claim 9. (currently amended) The method of ~~claim 1~~~~-any of claims 1-7~~, wherein the thrombolytic agent is first administered between about 24-48 hours after diagnosis of intraventricular hemorrhage, intracerebral hemorrhage, and/or subarachnoid hemorrhage.

Claim 10. (currently amended) The method of ~~claim 1~~~~-any of claims 1-9~~, further comprising performing CT scans at intervals of about 6-24 hours to monitor blood clot size and/or monitor whether bleeding is occurring.

Claim 11. (currently amended) The method of ~~claim 1~~~~-any of claims 1-10~~, wherein the thrombolytic agent is administered at least about every 4 hours.

Claim 12. (currently amended) The method of ~~claim 1~~~~-any of claims 1-11~~, wherein the thrombolytic agent is administered at least about every 6 hours.

Claim 13. (currently amended) The method of ~~claim 1~~~~-any of claims 1-12~~, wherein the thrombolytic agent is administered at least about every 8 hours.

Claim 14. (currently amended) The method of ~~claim 1~~~~-any of claims 1-13~~, wherein the thrombolytic agent is administered at least about every 10 hours.

Claim 15. (currently amended) The method of ~~claim 1~~~~-any of claims 1-14~~, wherein the thrombolytic agent is administered at least about every 12 hours.

Claim 16. (currently amended) The method of ~~claim 1~~~~-any of claims 1-15~~, wherein administration of the thrombolytic agent is stopped when the blood clot size is about 80% of its original size.

Claim 17. (original) The method of claim 16, wherein the blood clot reaches 80% of its original size about 3 days after the first administration of the thrombolytic agent.

Claim 18. (currently amended) The method of ~~claim 5~~ any of claims 5 or 7-17, wherein the urokinase is administered in doses of about 5000-50,000 units.

Claim 19. (original) The method of claim 18, wherein the urokinase is administered in doses of about 12,500 units.

Claim 20. (currently amended) The method of ~~claim 6~~ any of claims 6-17, wherein the t-PA or rt-PA is administered in doses of about 0.1-10 mg.

Claim 21. (cancelled)